Clinical Trial Update: Rucaparib(CO-338;Formally Called AG-014699 or PF-0136738) in Treating Patients With Locally Advanced or Metastatic Breast Cancer or Advanced Ovarian Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update evaluating the PARP inhibitor rucaparib in BRCA1/BRCA2 mutation carriers with locally advanced or metastatic breast cancer or ad…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Ovarian Cancer

Drugs mentioned

• Rucaparib (rucaparib)

Snippet

Sponsor: Cancer Research UK | Conditions: brca1 Mutation Carrier, brca2 Mutation Carrier | Phase 2 | Status: COMPLETED